New clinical data shows 20 percent reduction in patient radiation exposure with robotic-assisted intervention

May 20, 2020

Corindus, a Siemens Healthineers company and developer of precision vascular robotics, announced clinical results from a comparative study between robotic percutaneous coronary intervention (PCI) and manual PCI. Findings from the study show robotic PCI with the CorPath GRX System reduces patient exposure to radiation by 20% compared to manual PCI with no increase in fluoroscopy time or contrast utilization. 

The paper, titled “Comparison of Robotic Percutaneous Coronary Intervention with Traditional Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis of a Large Cohort,” published in Circulation: Cardiovascular Interventions discusses the study of 996 consecutive patients, of which 310 underwent robotic PCI and 686 underwent manual PCI. The study sought to measure air kerma (AK), dose area product (DAP), fluoroscopy time, volume of contrast and total procedural time. 

“These findings further represent the benefits of robotic-assisted intervention, particularly for patients,” stated Dr. Tejas Patel, Chairman and Chief Interventional Cardiologist of the Apex Heart Institute in Ahmedabad, Gujarat, India, and the lead investigator of the study. “The application of vascular robotics has shown other benefits through added precise device manipulation, and now, creates a safer environment for patients. I am honored to share my experience with the clinical community and to offer the benefits of this technology to my patients.” 

Interventional cardiologists experience the highest amount of radiation exposure of any medical professionals from fluoroscopy systems used in cardiovascular procedures, which can dramatically increase their risk for cancer, cataracts, and other radiation-related illnesses. The CorPath GRX design protects physicians by removing them from the radiation field and has been shown to reduce radiation exposure by over 95%. Dr. Patel’s study data proves robotic intervention also provides significant health benefits to patients by limiting radiation exposure as compared to a manual procedure. 

“The power of robotic intervention lies in its ability to increase patient and physician safety and improve clinical outcomes for delicate cardiovascular procedures,” said Mark Toland, CEO of Corindus. “Dr. Patel’s study validated our core beliefs and demonstrated a notable clinical benefit for patients undergoing robotic procedures. We see tremendous potential in health care to continue to make treatment paradigms safer and more effective through robotics and look forward to playing a significant role in that evolution.” 

Corindus has the release